E-scape Bio's Series A - II Round

E-scape Bio raised a round of funding on July 12, 2017.

E-scape is developing therapeutics against genetic targets for neurodegenerative disease including Alzheimer's Disease and Lewy Body Disease. E-scape's small molecule approach binds to mutated protein…

Articles about E-scape Bio's Series A - II Round: